STOCKS TELEGRAPH

Tag: Arrowhead Pharmaceuticals Inc.

  • Is This Why The ARWR Stock Is Falling Premarket Session Today?

    Arrowhead Pharmaceuticals Inc. (ARWR) shares were down -17.73% at $69.90 at the last check in pre-market trading. Arrowhead stock closed the last session at $84.96, an increase of 2.58% or $2.14. ARWR stock traded between the price range of $82.20 and $86.01. ARWR traded 0.69 million shares, down from 0.79 million in its 50-day average daily volume.

    Within the last 12 months, ARWR shares have grown 92.39%, and within the last week, they have decreased -5.08%. A total of 9.72% has been gained by the ARWR stock over the last six months, and a total of 26.67% has been gained over the last three months. ARWR stock has fallen since the company announced a clinical trial would be halted.

    Which study has ARWR paused?

    Arrowhead Pharma is dedicated to developing medicines that silence genetic causes of intractable diseases. ARWR therapies induce rapid, deep, and durable gene knockdown by triggering the RNA interference mechanism with a broad range of RNA chemistry options and efficient delivery methods. Living cells use RNA interference, or RNAi, to suppress the expression of certain genes, thereby affecting certain proteins. These natural pathways of gene silencing are utilized by ARWR’s RNAi-based therapeutics.

    Arrowhead today notified regulatory agencies, institutional review boards, and investigators it would be voluntarily pausing AROENaC1001, a Phase 1/2 clinical study of ARO-ENaC, effective immediately.

    • It was an investigational RNA interference (RNAi) therapy being developed by ARWR for patients with cystic fibrosis (CF).
    • ARWR made the decision after receiving a preliminary update from an ongoing chronic toxicology study that included unexpected evidence of lung inflammation in rats.
    • Until additional results from both the chronic rat toxicology study and an additional chronic primate toxicology study are reported, ARWR instructed investigators not to conduct new screening, enrollment, or further dosing of investigational ARO-ENaC.

    Arrowhead this week said its Phase 2b clinical study of ARO-ANG3 has dosed its first patient, an announcement that follows the first patient dosed in AROANG3-2001. ARWR was developing RNA interference (RNAi) therapeutics as a treatment for mixed dyslipidemia patients.

    How did the ARWR CEO respond?

    The CEO and president of Arrowhead Pharmaceuticals (ARWR), Christopher Anzalone, Ph.D., stated that although this is difficult news for cystic fibrosis patients who need new therapies, ARWR has an obligation to ensure that those enrolled in our clinical trials remain safe at all times.

    Arrowhead Pharmaceuticals (ARWR) believes that it needs to better understand the results from the chronic toxicology study in rats before proceeding with the current Phase 1 study, even though the data may not directly relate to the safety of continuing to treat patients.

    ARWR’s pulmonary program may have to wait a bit because of this, but it comes with drug development. ARWR will analyze the long-term toxicology data it receives as soon as possible to determine how it might affect ARO-ENaC and the patients it intends to serve.

  • Why Arrowhead Pharmaceuticals (NASDAQ: ARWR) Skyrocketed Today?

    Why Arrowhead Pharmaceuticals (NASDAQ: ARWR) Skyrocketed Today?

    Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) traded up 40.33% on Wednesday after it revealed the data on the drug to treat liver disease. Arrowhead has shared the positive interim 24-week liver biopsy results in four volunteers of AROAAT2002. AROAAT2002 is the open-label phase 2 clinical study of ARO-AAT. ARO-AAT is the investigational drug that is developed for the treatment of rare-genetic liver diseases. The rare liver disease is analogous with alpha-1 antitrypsin deficiency (AATD).

    The biotechnology company has revealed that the result of the study showed improvement in liver stiffness. The clinical trial has unveiled the positive effects of ARO-AAT as the company saw a reduction in intra-hepatic mutant AAT protein (Z-AAT), both Z-AAT monomer and Z-AAT polymer.  Participants have undergone the treatment for 24 weeks and all have shown the 93% to 95% drop in intrahepatic Z-AAT. Moreover, three of four patients have shown a 97% reduction in Z-AAT.

    Arrowhead earlier expected that the 6 months treatment with ARO-AAT will reduce both Z-AAT monomer and Z-AAT polymer but the 24 weeks treatment data has shown the results which are more than the expectations. The company is planning to discuss with the FDA and other regulatory agencies to speed up the clinical trial.

    Shares of Arrowhead Pharmaceuticals (NASDAQ: ARWR) soared 40.33% as it gained +13.63 at $47.43 during the trading session of Wednesday. In the past 52-weeks of trading, this company’s stock has fluctuated between the low range of $19.51 and a high range of $73.72. Arrowhead has traded up 143.10% from its 52-weeks low and traded down -35.66% from its 52-weeks high.  This company’s market capitalization has remained high, hitting $5.14 billion at the time of writing.

    The positive result from the 24-week treatment showed that the ARO-AAT will soon improve the liver injury. This encouraging result has also given hope to the Alpha-1 community in the midst of an ongoing pandemic.

    Arrowhead is currently working on the therapy, RNAi, that other companies have successfully commercialize. It has also licensed its therapies to various leading companies.  It is too early to say that it will get the EU or FDA approval but there are chances that the company will receive the approval as it has shown the positive results of phase 2 clinical study of ARO-AAT.

    Arrowhead three most advanced drugs include  ARO-AAT, a treatment for liver disease. The company has recently provided promising results from its phase 2, the second one is JNJ-3989 which is licensed to Janssen and it is the potential treatment for hepatitis B. It has earlier reported the data which also showed the encouraging result. The third one is the AMG 890. AMG 890 has the ability to decrease the production of apolipoprotein A which is genetically linked with increased risk of atherosclerosis and related cardiovascular diseases.